Verastem exercises option for exclusive ex-Asia rights to KRAS G12D inhibitor VS-7375

Verastem, Inc.

Exercised GenFleet option on Jan 14, 2025 for VS-7375, an oral, selective KRAS G12D (ON/OFF) inhibitor.
Rights cover worldwide development and commercialization outside mainland China, Hong Kong, Macau, and Taiwan.
Updated corporate presentation posted Jan 23, 2025; no specific financial or pipeline data disclosed in filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.